BRIEF published on 06/06/2024 at 13:05, 2 years 2 months ago Theralase détruit avec succès le cancer du poumon Technologies Théralase Cancer Du Poumon Rutherrin® Étude Préclinique
PRESS RELEASE published on 06/06/2024 at 13:00, 2 years 2 months ago Theralase(R) Successfully Destroys Lung Cancer Theralase® Technologies Inc. announces preclinical success with Rutherrin® compound in targeting Non-Small Cell Lung Cancer. Results show improved tumour destruction and slower progression Theralase Technologies Inc. Cancer Treatment Preclinical Study NSCLC Rutherrin Compound
BRIEF published on 06/04/2024 at 13:05, 2 years 2 months ago Theralase® Technology Effective in Virus Inactivation Theralase Ruvidar Antiviral Research Virus Inactivation Heliyon
BRIEF published on 06/04/2024 at 13:05, 2 years 2 months ago Technologie Theralase® efficace pour l'inactivation des virus Theralase Ruvidar Recherche Antivirale Heliyon Inactivation Des Virus
PRESS RELEASE published on 06/04/2024 at 13:00, 2 years 2 months ago Theralase(R) Technology Effective in Virus Inactivation Theralase Technologies Inc. announces successful inactivation of various viruses with lead compound RuvidarTM through peer-reviewed research. Potential for viral vaccine development highlighted Theralase Technologies Inc. RuvidarTM Peer-Reviewed Research Viral Inactivation Viral Vaccine Development
BRIEF published on 05/30/2024 at 13:05, 2 years 2 months ago Theralase Releases 1Q2024 Financial Statements Financial Results Cancer Treatment Theralase Study II PDCs
BRIEF published on 05/30/2024 at 13:05, 2 years 2 months ago Theralase publie ses états financiers du 1T2024 Résultats Financiers Traitement Du Cancer Theralase Étude II PDC
PRESS RELEASE published on 05/30/2024 at 13:00, 2 years 2 months ago Theralase(R) Release's 1Q2024 Financial Statements Theralase® releases unaudited interim consolidated 1Q2024 financial statements. Company to host conference call on June 6th, 2024. Study II update and Break Through Designation progress discussed Conference Call Financial Statements Break Through Designation Theralase Study II
BRIEF published on 04/24/2024 at 13:05, 2 years 3 months ago Theralase Technologies Inc. Completes $750,200 Funding Round Private Placement Pharmaceuticals Clinical Research Investment Theralase Technologies
BRIEF published on 04/24/2024 at 13:05, 2 years 3 months ago Theralase Technologies Inc. finalise une ronde de financement de 750 200 $ Investissement Placement Privé Médicaments Recherche Clinique Technologies Théralase
Published on 08/18/2026 at 02:20, 6 hours 57 minutes ago Numerous High-Grade Assays Extend Tolmer Silver Discovery
Published on 08/17/2026 at 22:30, 10 hours 47 minutes ago Matador Technologies Amends Convertible Note Facility to Expand At the Market Capacity and Commit a Fixed Share of Proceeds to Bitcoin
Published on 08/17/2026 at 21:00, 12 hours 17 minutes ago Taranis Announces New Critical Minerals By-Product Findings at the Thor and Ajax Mines
Published on 08/17/2026 at 15:00, 18 hours 17 minutes ago Norsemont Appoints Ariel Tepperman to Its Board
Published on 08/18/2026 at 09:05, 12 minutes ago How to Reduce Household Electricity Bills in Daily Life -- Sunshare Offers a New Solution
Published on 08/18/2026 at 09:05, 12 minutes ago Castrol ON PG25 cooling fluids validated for NVIDIA AI factory and data centre infrastructure
Published on 08/18/2026 at 09:00, 17 minutes ago Municipality Finance issues a SEK 1,25 billion tap under its MTN programme
Published on 08/18/2026 at 09:00, 17 minutes ago Original-Research: Readcrest Capital AG (von NuWays AG): BUY
Published on 08/17/2026 at 19:45, 13 hours 32 minutes ago Aéroports de Paris S.A - July 2026 traffic figures
Published on 08/17/2026 at 19:45, 13 hours 32 minutes ago Aéroports de Paris S.A - Trafic du mois de juillet 2026
Published on 08/17/2026 at 17:45, 15 hours 32 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/17/2026 at 17:40, 15 hours 37 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 10 au 14 août 2026 dans le cadre du programme de rachat d’actions.
